PRPiero Ricchiuto

Piero Ricchiuto

*This is an algorithmically generated author record based on publicly available information.

Piero Ricchiuto has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effect of Anselamimab on Cardiac Structure and Function in Patients With Light Chain Amyloidosis: Insights From the CARES Clinical Trials

    by Xiaowen Wang, Marianna Fontana, Brian Claggett, Karola S. Jering, Hicham Skali, Mathew S. Maurer, Piero Ricchiuto, Chen Yao, Hrishikesh Kulkarni, Haihong Li, et al.

  • Open Access

    Clinical Trial and Ontology-Derived Positive and Negative Benchmark Datasets for Drug Repurposing Across Rare Diseases

    by Cyrus Babak Ravandi, William R. Mowrey, Ayan Chatterjee, Fariba Khanshan, Parham Haddadi, Juan Carlos Mobarec, Simon Lambden, Tina Eliassi-Rad, Piero Ricchiuto, Gabriel Risa

    Evaluating the potential applications of a medicine is a fundamental challenge in drug development. There is a lack of standardized, decision-oriented benchmarks that test whether computational models can generalize therapeutic hypotheses across diseases in ways that reflect real-world pharmaceutical investment decision making. To address this gap, we introduce two complementary resources: the Indication Expansion Investment Decision Network (IxIDN) and the Orphanet Rare Disease Ontology Negative-network (ORDON). IxIDN is a clinical-trial-derived positive benchmark constructed by projecting drug–disease associations from pharmaceutical clinical trials into a disease–disease network; each edge connects disease pairs that have entered clinical trials for the same drug, thereby capturing cases when concrete indication-expansion decisions have been made. The current release contains 574 rare diseases and 5,336 edges. In contrast, ORDON serves as a stringent, biology-aware negative benchmark derived from the authoritative Orphanet Rare Disease Ontology. It identifies maximally distant disease pairs according to curated hierarchical structure and genetics-linked inheritance patterns, providing 793 rare diseases and 5,000 edges that represent high-separation negative candidates across therapeutic areas. Together, IxIDN and ORDON enable rigorous cross-evidence generalization from clinical trials to disease ontology, testing for Disease– Disease Association Learning (DDAL), a core task for mechanism-centered drug repurposing and indication expansion. All data are publicly available with detailed metadata, enabling reproducible evaluation of models on transparent, decision-relevant benchmarks.


  • Open Access

    Topology-driven negative sampling enhances generalizability in protein–protein interaction prediction

    by Ayan Chatterjee, Babak Ravandi, Parham Haddadi, Naomi H Philip, Mario Abdelmessih, William R Mowrey, Piero Ricchiuto, Yupu Liang, Wei Ding, Juan Carlos Mobarec, et al.

    Motivation: Unraveling the human interactome to uncover disease-specific patterns and discover drug targets hinges on accurate protein–protein interaction (PPI) predictions. However, challenges persist in machine learning (ML) models due to a scarcity of quality hard negative samples, shortcut learning, and limited generalizability to novel proteins. Results: In this study, we introduce a novel approach for strategic sampling of protein–protein noninteractions (PPNIs) by leveraging higher-order network characteristics that capture the inherent complementarity-driven mechanisms of PPIs. Next, we introduce Unsupervised Pre-training of Node Attributes tuned for PPI (UPNA-PPI), a high throughput sequence-to-function ML pipeline, integrating unsupervised pre-training in protein representation learning with Topological PPNI (TPPNI) samples, capable of efficiently screening billions of interactions. By using our TPPNI in training the UPNA-PPI model, we improve PPI prediction generalizability and interpretability, particularly in identifying potential binding sites locations on amino acid sequences, strengthening the prioritization of screening assays and facilitating the transferability of ML predictions across protein families and homodimers. UPNA-PPI establishes the foundation for a fundamental negative sampling methodology in graph machine learning by integrating insights from network topology. Availability and implementation: Code and UPNA-PPI predictions are freely available at https://github.com/alxndgb/UPNA-PPI.


  • Open Access

    Representation Learning of Human Diseases for Indication Expansion and Investment Decisions

    by Cyrus Babak Ravandi, William R. Mowrey, Ayan Chatterjee, Fariba Khanshan, Parham Haddadi, Michaël Ughetto, Ian Barrett, Wei Ding, Guillermo Del Angel, Tom Diethe, et al.

    A fundamental challenge in translational medicine is the computational modeling of complex human diseases to accelerate therapeutic development. Representation learning provides a powerful framework to address this, yet creating models that capture deep biological mechanisms remains a critical need. To this end, we propose a novel strategy that partitions the disease landscape into rare and non-rare categories, enabling systematic knowledge repurposing both within and between these groups. Here, we introduce Dis2Vec (Disease to Vector), a representation learning framework designed to operationalize this concept. Dis2Vec generates biologically grounded disease embeddings by learning from human genetic and phenotypic data, forming the foundation for Disease-Disease Association Learning (DDAL) and unsupervised disease clustering. We evaluate Dis2Vec representations in two downstream applications. First, we assess DDAL performance on a transfer learning benchmark designed to predict therapeutic transferability, using real-world drug repurposing investment decisions made in clinical trials. Second, unsupervised clustering analyses reveal shared biological mechanisms across diseases. By modeling the disease landscape in this way, Dis2Vec enhances translational research efficiency across both rare and non-rare diseases, advancing the development of foundational models for therapeutic science. Furthermore, Dis2Vec establishes a biologically grounded disease-representation and benchmarking layer that paves the way for trustworthy agentic biomedical AI systems in rare-disease indication expansion.

  • Open Access

    PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation

    by Hiroshi Iwata, Claudia Goettsch, Amitabh Sharma, Piero Ricchiuto, Wilson Wen Bin Goh, Arda Halu, Iwao Yamada, Hideo Yoshida, Takuya Hara, Mei Wei, et al.

    Despite the global impact of macrophage activation in vascular disease, the underlying mechanisms remain obscure. Here we show, with global proteomic analysis of macrophage cell lines treated with either IFNγ or IL-4, that PARP9 and PARP14 regulate macrophage activation. In primary macrophages, PARP9 and PARP14 have opposing roles in macrophage activation. PARP14 silencing induces pro-inflammatory genes and STAT1 phosphorylation in M(IFNγ) cells, whereas it suppresses anti-inflammatory gene expression and STAT6 phosphorylation in M(IL-4) cells. PARP9 silencing suppresses pro-inflammatory genes and STAT1 phosphorylation in M(IFNγ) cells. PARP14 induces ADP-ribosylation of STAT1, which is suppressed by PARP9. Mutations at these ADP-ribosylation sites lead to increased phosphorylation. Network analysis links PARP9–PARP14 with human coronary artery disease. PARP14 deficiency in haematopoietic cells accelerates the development and inflammatory burden of acute and chronic arterial lesions in mice. These findings suggest that PARP9 and PARP14 cross-regulate macrophage activation.


  • mIMT-visHTS: A novel method for multiplexing isobaric mass tagged datasets with an accompanying visualization high throughput screening tool for protein profiling

    by Piero Ricchiuto, Hiroshi Iwata, Katsumi Yabusaki, Iwao Yamada, Brett Pieper, Amitabh Sharma, Masanori Aikawa, Sasha A. Singh